Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Friday, November 12, 2010

Disability Status Scale Predicts Progression in MS

November 11, 2010

 A worsening of the Expanded Disability Status Scale lasting at least six months is effective in identifying disease progression in patients with relapsing-remitting multiple sclerosis, according to a study published in the November issue of the Archives of Neurology.




THURSDAY, Nov. 11 (HealthDay News) -- A worsening of the Expanded Disability Status Scale (EDSS) lasting at least six months is effective in identifying disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), according to a study published in the November issue of the Archives of Neurology.

In a retrospective analysis of the Multiple Sclerosis Collaborative Research Group study data, Richard A. Rudick, M.D., of the Cleveland Clinic, and colleagues evaluated patients with RRMS who received at least two years of treatment and completed an EDSS evaluation eight years post-randomization.
The investigators found that 45 patients had sustained six-month EDSS progression, while 115 patients did not. Eight years after randomization, progression was the strongest predictor of reaching EDSS milestones at the follow-up visit. The investigators also found that treatment arm assignment and baseline EDSS score were other independent predictors of reaching EDSS milestones at the follow-up visit.           Click here to continue









***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Gilenya Launch for Multiple Sclerosis Starts Slow for Novartis

November 11, 2010
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.


Summary

Gilenya became available in the US on Oct 4. Reports indicate just 13 enrollment forms within the first week. Numerous challenges lie ahead for a very effective therapy with very high expectations.

Analysis

Novartis has their work cut-out for them. While Gilenya holds the spotlight, the therapy has limited time before additional oral MS medications crowd the market. Gilenya comes with a significant monitoring requirement, along with safety concerns shared by both physicians and patients. Insurance coverage is a potential problem due to the pricing. Additional factors, along with market dynamics, make this launch and the ensuing year a challenge. Upcoming therapeutic agents in 2011 through 2013 are diverse, and may fill specific niches.




***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Wednesday, November 10, 2010

Study points to possible clues to faster MS progression

In a study of over 5,000 people with MS, researchers pinpointed motor symptoms at onset (such as muscle stiffness known as spasticity) and male gender as factors associated with a faster progression from relapsing-remitting MS to secondary-progressive MS. 

Marcus Koch, MD (University Medical Centre Groningen, The Netherlands), Helen Tremlett, PhD (University of British Columbia) and colleagues report on the findings in the Journal of Neurology, Neurosurgery, and Psychiatry (2010 Jul 16. 

Researchers were funded by the National MS Society, the MS Society of Canada and others.

Both Dr Koch and Dr Tremlett are former recipients of Du Pré grants from MSIF.


Read more, as reported by the NMSS




***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Survey highlights gap between patient and healthcare professional perceptions of mobility loss due to multiple sclerosis

New research into mobility impairment in multiple sclerosis (MS) has revealed a gap between the perceptions of people with MS and their healthcare professionals.

According to the survey, healthcare professionals think more than half (56%) of people with MS under their care experience some loss of mobility, while published data reveal that up to 85% of people with MS suffer from impaired mobility.

The survey, which was commissioned by pharmaceutical company Biogen Idec, investigated the experiences of people with MS in Canada, France, Germany, Spain, Sweden and the United Kingdom. More than 400 people with MS and 180 healthcare professionals were surveyed.

The findings are supported by two recent pieces of research which have shown that walking ability is insufficiently monitored in people with MS by healthcare professionals and that 39% of people with MS and 49% of care partners never or rarely discuss mobility issues with a physician.

In addition, the survey underscored the impact of mobility impairment on employment and the social lives of people with MS. Of those surveyed:     CLICK to Continue




***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Quebec doctor warns of 'liberation treatment' risks


Updated: Wed Nov. 10 2010 10:04:08 AM

CTV.ca News Staff
The president of the Quebec Association of Radiologists says he agrees with a warning issued by Quebec doctors to multiple sclerosis patients urging them not to seek the "liberation" treatment at clinics outside Canada.
Dr. Frédéric Desjardins says the balloon angioplasty used in the liberation treatment carries known risks that are not insignificant.
The procedure involves inserting a catheter into a vein and then inflating a balloon to unblock the vein. While angioplasty is performed every day on heart patients with blocked coronary arteries, Desjardins warns it is not risk-free.
"We don't know the benefits of this procedure and the procedure has some risks to it. So in medicine, it's always a balance between risk and benefit," he told CTV's Canada AM Wednesday morning from Montreal.
Desjardins explained that there are known complications from angioplasty, including the possibility of thrombosis, which is the formation of a blood clot inside a blood vessel. The procedure can also cause an embolism, which is a clot that travels along a vessel until it clogs the vessel, or a CVA (cerebrovascular accident), also known as a stroke.


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************